Oncology Central

Prioritizing uncharacterized genes in the search for glioma biomarkers

0

A total of 40% of all primary CNS tumors are diagnosed as gliomas, with glioblastomas (GBM) being the most malignant [1]. There is a very poor survival time of approximately 15 months for most patients diagnosed with GBM [1]. The malignant nature of high grade gliomas makes them one of the leading causes of cancer death [1]. To classify tumors and assess prognosis, differences in molecular composition, or ‘biomarkers’, between tissue types can be used diagnostically to assess and manage adult malignant gliomas [2–7].

To view restricted content, please:
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.